Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy

Figure 1 Changes in liver inflammation between pretreatment and posttreatment liver biopsies in individual patients. A: Change in periportal or periseptal interface hepatitis; B: Change in confluent necrosis; C: Change in focal lytic necrosis; D: Change in portal inflammation.

Figure 2 Histology of two “probably reversing” cases before and after sustained virologic response with direct-acting antivirals. Patient 1 is a 55-year-old male with genotype 1b treated with daclatasvir + asunaprevir for 24 wk: Pre-histology activity index (HAI) 14, pre-Ishak 6, pre-predominantly progressive, indeterminate and predominately regressive (P-I-R) predominantly progressive, post-HAI 4, post-Ishak 6, post-P-I-R predominantly progressive. Patient 2 is a 39-year-old female with genotype 3 treated with sofosbuvir + ribavirin for 24 wk: Pre-HAI 6, pre-Ishak 3, pre-P-I-R indeterminate, post-HAI 3, post-Ishak 3, post-P-I-R predominately regressive. Hematoxylin and eosin (10 ×); Masson’s trichrome (4 ×); reticulin (4 ×). H/E: hematoxylin and eosin.